Authors
Pouria Abedi, Mojgan Mohammadi, Hediye Ahouei, Sara Azimi, Sajad Dehnavi, Mahvash Sadeghi
Published in
International immunopharmacology. Volume 192. Pages 117674. Nov 14, 2026. Epub Nov 14, 2026.
Abstract
The tumor microenvironment (TME) is a complex ecosystem in which macrophages, particularly tumor-associated macrophages (TAM), play an important role. The inflammatory M1 phenotype has been shown to exert potent antitumor activities. However, the TME often subverts these cells into a M2 polarized state, promoting immune evasion, angiogenesis, and metastasis. Consequently, the strategic reprogramming or "repolarization" of TAMs from a pro-tumorigenic M2 state to an antitumor M1 phenotype has emerged as a transformative frontier in cancer immunotherapy. This review provides a comprehensive analysis of the biological, metabolic, and signaling frameworks that govern macrophage plasticity. Additionally, it explores the innovative application of "nanosized armors" in orchestrating this phenotypic shift. We initiated our investigation by delineating the biogenesis and functional diversity of macrophages, emphasizing the signaling pathways and metabolic shifts that dictate polarization. Next, we classified and evaluated various nanoplatforms designed for M1 induction, categorized into: (i) synthetic nanoparticles for precise cargo delivery; (ii) lipid-based systems offering high biocompatibility; (iii) inorganic nanomaterials that leverage intrinsic immunomodulatory properties and facilitate image-guided therapy; (iv) hybrid and biomimetic vesicles that combine structural stability with biological functionality; and (v) extracellular vesicles (EV) and Exosomes (Exo), highlighting their unique role as "natural delivery systems" with enhanced targeting capabilities. We further examined how these platforms deliver diverse cargoes-including small molecules, nucleic acids, cytokines, and toll-like receptor (TLR) agonists-to bypass biological barriers and achieve spatial-temporal control over macrophage behavior. By integrating immunology with advanced nanotechnology, these "nanosized armors" offer a robust toolkit to overcome the immunosuppressive TME. This review concludes by addressing the current challenges in clinical translation and the future potential of these platforms in combinational and personalized immunotherapy.
PMID:
43033539
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0